Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AG-024322 is a potent ATP-competitive inhibitor of pan-CDK against cell cycle kinases CDK1, CDK2, and CDK4(Ki values in the 1-3 nM range)
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 3,530 | 5日内发货 | ||
25 mg | ¥ 13,900 | 6-8周 | ||
50 mg | ¥ 18,300 | 6-8周 | ||
100 mg | ¥ 23,500 | 6-8周 |
产品描述 | AG-024322 is a potent ATP-competitive inhibitor of pan-CDK against cell cycle kinases CDK1, CDK2, and CDK4(Ki values in the 1-3 nM range) |
靶点活性 | CDK2:3 nM (ki), CDK1:2.3 nM (ki), CDK4:2.9 nM (ki) |
体外活性 | AG-024322 (0.1-30 μM; 24 hours) is less toxic at concentrations below 3 μM. The viability of human PBMCs as measured by ATP content with a TC50 value of 1.4 μM for human PBMCs[2]. It is slightly less potent in the functional cellular assay with an IC50 of 120 nM[2]. AG-024322 (0-120 nM) exhibits growth inhibition effects on HCT-116 cells. |
体内活性 | AG-024322 (intravenous infusion; 2, 6, and 10 mg/kg; 5 days) exhibits no-adverse-effect at 2 mg/kg with mean plasma AUC (0-24.5) of 2.11 g.h/mL. At 6 mg/kg produces pancytic bone marrow hypocellularity, lymphoid depletion. And vascular injury at the injection site renal tubular degeneration occurs at 10 mg/kg[1]. AG-024322 (20 mg/kg) causes a 65% TGI in the MV522 tumor model. It results a 52% TGI at 1/2 of the maximum tolerated dose (MTD) and only slight anti-tumor activity at 1/4 of the MTD[3]. AG-024322 (20 mg/kg) inhibits the growth of established human tumor xenografts of different origins with tumor growth inhibition (TGI) ranging from 32% to 86.4% and it also exhibits anti-tumor effects as a dose-pdependent manner[3]. |
分子量 | 418.44 |
分子式 | C23H20F2N6 |
CAS No. | 837364-57-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AG-024322 837364-57-5 Cell Cycle/Checkpoint CDK AG 024322 AG024322 Inhibitor inhibitor inhibit